RE: Posted on ADVFN AI summary12 May 2026 08:26
Given where the company was this time last year - clapped out penny stock that looked like de-listing material for most - this is a HUGE deal and common sense suggests there should be a significant re-rate.
AIM being AIM, there's no immediate promise of mountains of gold, we'll probably end the day in the red.
Given where the company was this time 5 years ago, the news is interesting, but we'll only know the real value of the deal after the RSH equity funding round (presumably, when it's being taken to clinical).
I still wish I sold out at 1.50 when I had a chance. I'd take 75 for my tickets any day.